BioNTech SE
Healthcare · EUR · XETRA
Price
€79.8
Cap
€22.44B
Earnings
—
30d Trend
-8.1%
58% annualised over 90 days
BRAIN47 SIGNAL
Raw weighted: 45×Macro 0.99 (−1%)=45
RISK
QUALITY
MOMENTUM
TECHNICAL
FUNDAMENTALS
Macro: neutral (×0.99) - Fear/Greed: 64 (Greed) - Data: 100%
BRAIN47 HORIZON ANALYSIS
Limited short-term thesis
BRAIN47'S ASSESSMENT
I rate BioNTech SE at 45/100 — a MODERATE reading on the Brain47 Signal. The strongest factor is fundamentals at 55/100. I classify this as a speculative position with the strongest thesis on a short-term horizon.
PAST PERFORMANCE
1 MONTH
-7.2%
3 MONTHS
-14.6%
12 MONTHS
-8.9%
Trailing returns — past performance, not a projection.
DETAILED ANALYSIS
Limited short-term thesis. Fundamentals (55) and Technical (49) are the primary strengths. I note an elevated risk profile — this warrants closer monitoring. Historical volatility is elevated at 58%. I classify this as a speculative position — elevated volatility at 58% and asymmetric payoff potential define the opportunity.
Want full analysis on every stock?
Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.
Join Brain47 — FreeGenerated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.